ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

CTEC Convatec Group Plc

286.00
-3.20 (-1.11%)
Last Updated: 14:10:44
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Convatec Group Plc LSE:CTEC London Ordinary Share GB00BD3VFW73 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.20 -1.11% 286.00 285.80 286.20 290.20 286.00 290.20 967,738 14:10:44
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 2.14B 130.3M 0.0636 45.00 5.87B

ConvaTec Group PLC Changes within U.S. Home Distribution Group (4605G)

02/03/2018 7:00am

UK Regulatory


Convatec (LSE:CTEC)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Convatec Charts.

TIDMCTEC

RNS Number : 4605G

ConvaTec Group PLC

02 March 2018

ConvaTec announces changes within its U.S. Home Distribution Group

Reading, United Kingdom (02 March 2018) - ConvaTec Group Plc ("ConvaTec") a leading global medical products and technologies company focused on therapies for the management of chronic conditions, today announces the acquisition of J&R Medical LLC ("J&R Medical"), a Texas-based independent distributor of catheter-related supplies. For the year ended 31 December 2017 J&R Medical delivered revenues of approximately $9.0 million.

Paul Moraviec, CEO of ConvaTec, said: "The addition of J&R Medical to our Home Distribution Group will strengthen our presence in a substantial and important US market. The acquisition also reinforces ConvaTec's position as a leading distributor of urinary catheters in the US."

Concurrently with this strategic addition to the US Home Distribution Group, ConvaTec has divested its respiratory delivery business in Arizona and Utah. The net financial impact to ConvaTec of these transactions is positive in both revenue and EBITDA.

Enquiries

Media

   Bobby Leach, VP Group Corporate Affairs, ConvaTec                    +44 (0)7770 842 226 

Alastair Elwen, Finsbury +44 (0)207 251 3801

Analysts and Investors

   John Crosse, VP Investor Relations, ConvaTec                             +44 (0)7500 141 435 
   Kirsty Law, Director Investor Relations, ConvaTec                         +44 (0)7470 909 582 

investorrelations@convatec.com

About ConvaTec

ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. ConvaTec's products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.

# # #

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCUAABRWAAORAR

(END) Dow Jones Newswires

March 02, 2018 02:00 ET (07:00 GMT)

1 Year Convatec Chart

1 Year Convatec Chart

1 Month Convatec Chart

1 Month Convatec Chart

Your Recent History

Delayed Upgrade Clock